2bind GmbH

The 2bind GmbH is a provider of biophysical analytical services. Our main focus is on early drug discovery phases. Our mission is to assist our customers and collaboration partners with our biophysical assays. In addition, we offer assays to characterize protein stability and aggregation tendency.

Our team of experts can help in HTS assays to identify potent binding partners of a drug target. In addition, our assays allow to characterize a lead candidate in terms of basic binding parameters such as binding affinity, kinetics and thermodynamics. Last but not least, we can assist with assays to understand the MOA of a specific drug.

Our assays are based on different technologies:

1. MicroScale Thermophoresis
   Our MicroScale Thermophoresis (MST) assays help to study the interaction between target protein and drug candidate(s). We offer a broad assay range from library screens, validation assays, competition assays and so on. Basic binding parameters such as affinity, stoichiometry and thermodynamics can be determined. MST is fast, precise, offers free choice of buffer and low sample consumption.

2. Biolayer Interferometry
   BLI is a surface based method, allowing to study kinetics of molecular interactions

3. Isothermal titration calorimetry
   ITC is an in-solution method, enabling to study thermodynamics of molecular interactions without modification of the interaction partners.

4. nanoDSF assay
   Our nanoDSF services offer information on the folding and the stability of the target protein. Buffer or detergent screens are used to determine optimal conditions for the target protein in terms of stability. Furthermore, quality controls as well as ligand screens can be performed using this innovative technology. nanoDSF works without modification of the target protein, with free choice of buffer and low sample consumption

Our worldwide customers are mainly biotech and pharma companies as well as scientists from universities. Their main interest field are drug development, antibody discovery, epigenetics and aptamer development.

Up to date we have finished over 350 projects with 6 of the top 10 pharma companies, more than 60 biotech companies and over 25 universities.